Abstract
This chapter deals with the approved and marketed anticancer drugs derived
from marine sponges, mollusks/cyanobacteria, and tunicates; marine biota-derived
anticancer compounds in clinical trials i.e in III, II, and I phases; and bioactive new
chemical entities (NCEs) with anticancer function from marine biota. Limiting factors
in the development and approval of drugs from marine biota and significant challenges
in the development and approval of marine drugs are also given.
About this chapter
Cite this chapter as:
Ramasamy Santhanam, Santhanam Ramesh, Subbiah Balasundari, Sheba R. David ;Marine Biota-based Anticancer Drug Candidates in Pipeline, Anticancer Drugs Sourced from Marine Life Medicinal Chemistry and Marine Life (2024) 1: 20. https://doi.org/10.2174/9789815256055124010005
DOI https://doi.org/10.2174/9789815256055124010005 |
Publisher Name Bentham Science Publisher |